AURORA Study-A Transformative Approach to Support PrEP Medication Persistence

Status unconfirmed

Conditions studied: HIV Infections

In brief

This study is designed to test the hypothesis that, compared to oral PrEP, use of CAB-LA in underserved populations in a real-world setting supported by a digital health companion program will be associated with greater medication adherence, persistence, retention-in-care, and improved PROs. Patients in the study will receive current standard care for HIV prevention and be offered enrollment in the digital health companion program. Goal of the study is to evaluate medication adherence and persistence in patients receiving CAB-LA vs oral PrEP and who engage with a digital health companion program.

Key facts

Study ID

NCT06072443

Run by

WV Health Right, Inc.

People needed

105

Starts

2023-11-30

Expected to finish

2025-06-30

Last updated by the study team

2024-06-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Initiation of or current user of PrEP with CAB-LA, daily FTC/TDF, or daily FTC/TAF prescribed in accordance with the WVHR standard of care practices (based practices on CDC PrEP 2021 Clinical Practice Guidelines) by a licensed HCP
• PrEP dispensed by WVHR pharmacy
• Access to a smart phone

You may not qualify if…

• Receiving HIV PrEP care outside of WVHR
• Positive HIV diagnosis
• Contraindication to oral or injectable PrEP therapy
• Receiving oral bridging therapy prior to injectable PrEP therapy

Where it is running

• West Virginia Health Right — Charleston, West Virginia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.